11th International Conference on Cachexia, Sarcopenia and Muscle Wasting December 7-9, 2018 – Maastricht, The Netherlands
Email address *
Last name
Your answer
First name
Your answer
Your answer
1. Was this conference helpful for your clinical practice?
2. Was this conference helpful to keep you up to date regarding the latest advancements in the field?
3. Was the programme objective, balanced and free of commercial bias?
4. What were the most effective aspects of this conference, and why?
Your answer
5. What were the least effective aspects of this conference, and why?
Your answer
6. Which topics would you suggest for future conferences?
Your answer
7. Compared with other educational activities, this conference was:
8. Do you have any comments or suggestions regarding the SCWD website (www.society-scwd.org)?
Your answer
9. Please rate the following presentations (Friday, December 7):
A. Clinical and societal impact of cachexia & sarcopenia
Recent facts & figures - S. von Haehling
Clinicians quest: geriatrician – F. Landi
Clinicians quest: medical oncologist – F. Strasser
Surgeon and patient quest – S. Olde Damink
B. Workshops: Innovation & implementation
Workshop 1: Novel methodologies in basic cachexia research
Workshop 2: Innovative approaches in human metabolic research
Workshop 3: Metabolic risk & outcome assessment
Workshop 4: Rehabilitation and advanced care planning
Workshop 5: Where science meets art: preserving and authenticating old master paintings
10. Please rate the following presentations (Saturday, December 8):
C. Multi-layered triggers of chronic disease associated wasting
Acute events upon chronic wasting in COPD: Clinical perspective – F. Franssen
Acute events upon chronic wasting in COPD: Basic research insights – R. Langen
Striated muscle pathology in cardiac cachexia: Clinical perspective – M. Lainscak
Striated muscle pathology in cardiac cachexia: Basic research insights – J. Springer
Chronic kidney disease + accelerated aging: Clinical perspective – K. Kalantar-Zadeh
Chronic kidney disease + accelerated aging: Basic research insights –X. H. Wang
D. Late breaking clinical trials & trial updates
Resistance training to build muscle mass in stage II and III colorectal cancer patients – B. Caan
The effect of a six-month intensive strength training and strength-endurance training on muscle strength and body composition in older adults: A randomized controlled trial (1-21) – K. Liberman
Αcute effects of essential amino acid gel-based and whey protein supplements on appetite and energy intake in older women (5-04) – T. Ispoglou
BIO101 accelerates differentiation and enhances mitochondrial function in skeletal muscle cells (4-11) – M. Serova
Short-term creatine supplementation reduces the malnutrition-inflammation score and attenuates lean body mass loss in hemodialysis patients (6-06) – G. Pimentel
Update on ACTA agents for cancer cachexia – A. Coats
Development of botanical drug from purified ginseng extract for the treatment of cancer cachexia – J. K. Lee
E. Clinical track: Emerging fields in critical illness wasting
Muscle metabolism and physiology in chronic critical illness – Z. Puthucheary
Linking critical illness, chronic inflammation, and long-term muscle dysfunction – D. Griffith
Persistent inflammation immunosuppression catabolic syndrome – S. Brakenridge
Novel approaches to skeletal muscle loss in alcohol use and alcoholic liver disease – S. Dasarathy
NT-proBNP levels predict worse long-term physical function and muscle strength in sepsis survivors (1-28) – R. Mankowski
F. Basic track: Tumor- and host-derived triggers of cachexia
Inflammation and control of muscle mass – J. Carson
Muscle-derived growth factors and muscle atrophy – V. Romanello
Tumor-derived Hsp-70/90 in cancer cachexia – Y.-P. Li
Transfer of enzymatic activity of tumor-borne extracellular vesicles – M. Berriel Diaz
Tumor gp130 ligands expression and release in cancer cachexia – T. Zimmers
G. Clinical track: Challenges of cancer induced wasting in the older patient
Update on treatment options for cancer cachexia – M. Muscaritoli
When cancer cachexia occurs with sarcopenia – A. Jatoi
Proteomics and sarcopenia/frailty – L. Ferrucci
Controversies of comprehensive geriatric assessment in weight losing cancer patients – P. Ravasco
Complex decision making in the older, weight-losing cancer patient – A. Laviano
Towards a more comprehensive understanding of the barriers to implementing nutritional advice in patients with cancer cachexia (6-02) – R. T. Jagoe
H. Basic track: Experimental models
In vitro muscle culture: Muscling in on the third dimension – L. Thorrez
Mouse avatars in cancer cachexia – A. Judge
Natural (large animal) models of sarcopenia and cachexia – L. Freeman
An innovative experimental setup for characterizing in vivo muscle weakness in mouse models of cancer cachexia (3-30) – J. Gondin
Novel models of human pancreatic cancer cachexia heterogeneity by tumor organoids transplantation into mice (4-05) – M. Aberle
Characterization of the endotoxin induced cachexia preclinical model (2-30) – O. Bezy
I. Clinical track: Management guidelines for sarcopenia
Rapid screening for sarcopenia – J. E. Morley
The added value of the concepts of frailty and sarcopenia in the development of a proactive elderly care – J. Schols
Screening for sarcopenia, frailty and anorexia in the community – T. Malmstrom
Guidelines for management of sarcopenia – J. Bauer
The natural course of body composition in hemodialysis patients (1-55) – W. J. Visser
Sex differences in the relationship of concurrent change in knee extension peak torque and body composition with change in gait speed (1-14) – Y. Osawa
J. Novel Nutritional and pharmacological targets in cachexia & sarcopenia
Epigenetic targeting of bromodomain protein BRD4 – G. Caretti
Non-classical targets in cancer cachexia: liver metabolism – S. Herzig
GDF11/15 in skeletal muscle wasting – D. Glass
PDK4 drives metabolic alterations and skeletal muscle atrophy in cancer cachexia – A. Bonetto
Multi-organ nutritional targets – J. Argiles
K. Rapid fire abstract session
Cross-sectional associations of n-6 plasma phospholipid fatty acids with circulating C-reactive protein and skeletal muscle mass in the EPIC-Norfolk cohort (1-01) – R. P.G. Hayhoe
Longitudinal muscle and myocellular changes in community-dwelling men over two decades of successful aging - The ULSAM cohort revisited (1-30) – E. Skoglund
Prognostic role of muscle, fat, and bone mass in heart failure (1-39) – M. Konishi
Effects of mitochondrial targeting with SS-31 in cancer-induced muscle wasting (2-03) – R. Ballarò
Integrative transcriptome and miRNAome analysis reveals extracellular matrix remodeling during muscle atrophy in cancer cachexia (2-12) – G. J. Fernandez
Depot specific adipose mRNA transcriptomics in cancer cachexia (2-20) – J. Miller
Identification of potential cancer cachexia biomarkers by tumor transcriptome analysis in non-small cell lung cancer patients with low muscularity (2-27) – S. Santiloni Cury
Detection of sarcopenia and cachexia during the recording of the routine 12 channel ECG (Combyn™ ECG) (4-01) – F. Skrabal
Muscle microRNAs predict muscle wasting following cardiac surgery (4-02) – P. Kemp
Skeletal muscle collagen content is increased in cachectic pancreatic cancer patients and is a significant predictor of survival (5-08) – S. M. Judge
11.Please rate the following presentations (Sunday, December 9):
L. Multi-layered triggers of cancer cachexia
Dysphagia in sarcopenia and head and neck cancer – H. Wakabayashi
IL-6 trans-signaling among tumor, muscle and fat mediates pancreatic cancer cachexia (2-28) – J. Rupert
Inflammation-adipocyte crosstalk in muscle wasting – M. Seelaender
Tumor-induced immune- and metabolic reprogramming – T. Flint
Influence of the gut microbiota on anticancer immunosurveillance – A. Elkrief
Mechanisms of chemotherapy-induced muscle wasting – R. Kivelä
M. Basic track: (Intra)cellular mechanisms of muscle wasting
Altered muscle proteostasis in muscle wasting – M. Sandri
Role of microRNAs in muscle wasting – P. Costelli
Muscle progenitor cell function and muscle wasting – D. Guttridge
Inflammatory and glucocorticoid signaling in muscle atrophy – R. Hardy
Bloom of Enterobacteriaceae in cancer cachexia: Klebsiella oxytoca as a gut pathobiont contributing to intestinal dysfunction (3-22) – L. B. Bindels
N. Translational track: Anabolic resistance in sarcopenia and cachexia: Myth or opportunity?
Sarcopenic obesity – Y. Boirie
Physical inactivity accelerates sarcopenia and leads to metabolic dysfunction – L. van Loon
Exercise as therapeutic approach in cancer cachexia – F. Penna
Cell therapy for muscle injury - preclinical model and clinical application – T. Winkler
Leucine nutritional supplementation modulates the tumour-induced alteration in energy metabolism and production in skeletal muscle activity (6-10) – M. C. Cintra Gomes-Marcondes
Distinct skeletal muscle molecular responses to pulmonary rehabilitation in COPD: a cluster analysis (1-48) – A. E.M. Kneppers
Prolonged exercise training improves acute type II skeletal muscle fiber stem cell response in healthy older men (1-23) – T. Snijders
O. Omics approaches in cachexia & sarcopenia research
Extra-cellular vesicles in tissue crosstalk during exercise – M. Whitham
Lipidomics and transcriptomics – I. Gallagher
Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle – S. Acharyya
Small RNAome profiling of skeletal muscle in cancer cachexia - S. Damaraju
P. Novel intervention strategies and clinical study designs
Cancer cachexia development update – S. Anker
Nutrition & pharma joining forces – A. Schols
P4 medicine in cachexia & sarcopenia – J. Morley
The regulators’ update: EMA, cachexia and sarcopenia – G. Rosano
Q. Highlights session
Treatment – A. Coats
Imaging – S. Heymsfield
Biomarker/Sarcopenia – S. von Haehling
Basic – D. Attaix
A copy of your responses will be emailed to the address you provided.
Never submit passwords through Google Forms.
This content is neither created nor endorsed by Google.